Roundtable

Genomic Medicine and Genetic Counseling in the Department of Veterans Affairs and Department of Defense

Author and Disclosure Information

 

Lisa Arfons. First and foremost, I tell the patient that it is a discussion with a genetic counselor. I make it clear that they understand that it is a discussion. They then can agree or not agree to accept genetic testing if it’s recommended.

I talk in general terms about why I think it can be important for them to have the discussion, but that we don’t have great data for decisionmaking. We understand that there are more options for preventive measures but then it ultimately will be a discussion between the PCP, the patient, and their family members about how they proceed about the preventive measures. I want them to start thinking about how the genetic test results, regardless of if they are positive, negative, or a variant that is not yet understood, can impact their offspring.

Probably I am biased, as my mom had breast cancer and she underwent genetic testing. So, I have a bit of an offspring focus as well. I already mentioned that you must discuss about whether or not it’s worth screening or doing any preventive measures on contralateral breast, or screening for things like prostate cancer at age 75 years. And so I focus more on the family members.

I try to stay in my lane. I am extremely uncomfortable when I hear about someone in our facility sending off a blood test and then asking someone else to interpret the results and discuss it with the patient. Just because it’s a blood test and it’s easy to order doesn’t mean that it is easy to know what to do with it, and it needs to be respected as such.

Ishta Thakar. Our PCPs let the patients know that GMS will contact the patient to schedule a video appointment and that if they want to bring any family members along with them, they’re welcome to. We also explain that certain cancers are genetically based and that if they have a genetic mutation, it can be passed on to their offspring. I also explain that if they have certain mutations, then we would be more vigilant in screening them for other kinds of cancers. That’s the reason that we refer that they get counseled. After counseling if they’re ready for the testing, then the counselor orders the test and does the posttest discussion with the patient.

Vickie Venne. In the VA, people are invited to attend a genetic counseling session but can certainly decline. Does the the DoD have a different approach?

Maj De Castro. I would say that the great majority of active duty patients have limited knowledge of what to expect out of a genetics appointment. One of the main things we do is educate them on their rights and protections and the potential risks associated with performing genetic testing, in particular when it comes to their continued ability to serve. Genetic testing for clinical purposes is not mandatory in the DoD, patients can certainly decline testing. Because genetic testing has the potential to alter someone’s career, it is critical we have a very thorough and comprehensive pre- and posttest counseling sessions that includes everything from career implications to the Genetic Information Nondiscrimination Act (GINA) and genetic discrimination in the military, in addition to the standard of care medical information.

Pages

Recommended Reading

VHA Practice Guideline Recommendations for Diffuse Gliomas (FULL)
Federal Practitioner
Prevalence of Cancer in Thyroid Nodules In the Veteran Population (FULL)
Federal Practitioner
Real-world data for immunotherapy-treated NSCLC found robust
Federal Practitioner
Clopidogrel matches aspirin for reducing risk of colorectal cancer
Federal Practitioner
FDA approves darolutamide for nonmetastatic CRPC
Federal Practitioner
COPD adds complexity to shared decision making for LDCT lung cancer screening
Federal Practitioner
Bevacizumab or pemetrexed, but not both, efficacious for NSCLC maintenance
Federal Practitioner
Accuracy of Endoscopic Ultrasound in Staging of Early Rectal Cancer (FULL)
Federal Practitioner
Review of Radiologic Considerations in an Immunocompetent Patient With Primary Central Nervous System Lymphoma (FULL)
Federal Practitioner
Use of Mobile Messaging System for Self-Management of Chemotherapy Symptoms in Patients with Advanced Cancer (FULL)
Federal Practitioner

Related Articles

  • Article

    VHA Practice Guideline Recommendations for Diffuse Gliomas

    Although histology still plays a critical role in diagnosing diffuse gliomas, additional ancillary testing is an essential tool for VA pathology...

  • Best Practices

    Caring for Patients With Prostate Cancer Who Are BRCA Positive

    Genomic testing may be a vital component in the medical management of patients with complex clinical phenotypes and cancer.